MIK665 CAS No.: 1799631-75-6

MIK665 CAS No.: 1799631-75-6 - The Solution for Promising Cancer Therapies

MIK665 CAS No.: 1799631-75-6 is a breakthrough drug that has been shown to be effective against cancer cell proliferation. It is an oral drug, designed specifically to target the Mcl-1 protein, which is a crucial factor responsible for the survival of cancer cells. Its mechanism of action leads to the prevention of cell growth, and therefore cancer cell death.

With over 18 million new cancer cases each year worldwide, and nearly 10 million cancer-related deaths, cancer continues to be a significant health burden globally. Patients with cancer must undergo a range of treatments, including chemotherapy, radiation, and surgery, which can damage normal healthy tissues and cause severe side effects. In addition, most current treatments are unable to target the specific molecules responsible for cancer cell survival, leading to drug resistance and treatment failure. With the development of MIK665 CAS No.: 1799631-75-6, a new promising cancer therapy could revolutionize current treatment options.

MIK665 CAS No.: 1799631-75-6 is a promising drug that targets Mcl-1 protein in cancer cells, which is not targeted by other drugs. The drug has the potential to be used to treat various types of cancers, including leukemia, lymphoma, multiple myeloma, and solid tumors.

One of the significant benefits of MIK665 CAS No.: 1799631-75-6 is that it can be administered orally, making it convenient for patients to take, avoiding hospital visits and reducing treatment costs. Preclinical studies have shown that MIK665 CAS No.: 1799631-75-6 is well-tolerated and is not associated with significant side effects, making it an ideal candidate for cancer treatment.

Clinical trials of MIK665 CAS No.: 1799631-75-6 have shown that it is effective in reducing cancer cell growth and inducing cell death. In a phase 1 clinical trial, patients with lymphoma and multiple myeloma were treated with MIK665 CAS No.: 1799631-75-6, and the drug showed promising results in reducing cancer cell proliferation with manageable side effects.

In addition to its efficacy, MIK665 CAS No.: 1799631-75-6 is versatile and can be used in combination with other cancer therapies, including chemotherapy and radiation, to increase their effectiveness. The combination therapy could significantly improve the outcome of cancer treatment while avoiding severe side effects of chemotherapy and radiation.

MIK665 CAS No.: 1799631-75-6 has enormous potential in the field of cancer treatment, and its development could change the paradigm of cancer therapy. Pharmaceutical companies, researchers, and clinicians are all keenly interested in the drug and its potential applications in cancer treatment.

In conclusion, MIK665 CAS No.: 1799631-75-6 is a promising cancer therapy that specifically targets the Mcl-1 protein in cancer cells, leading to cell death. It is well-tolerated, versatile, and can be used in combination with other cancer therapies to increase their effectiveness. With its potential application in various cancer types, MIK665 CAS No.: 1799631-75-6 is poised to revolutionize current cancer treatment options.

Chemical Structure: MIK665

CAS No.: 1799631-75-6

 

MIK665(MIK 665, S 64315, S64315)

Catalog No.: URK-V595  Only Used For Lab.

MIK665 (S-64315, MIK-665) is a novel potent, selective Mcl-1 inhibitor (IC50=1.8 nM) with potential pro-apoptotic and antineoplastic activities.

Biological Activity

MIK665 (S-64315, MIK-665) is a novel potent, selective Mcl-1 inhibitor (IC50=1.8 nM) with potential pro-apoptotic and antineoplastic activities.
MIK665 (S-64315) binds to and inhibits the activity of Mcl-1, which promotes apoptosis of cells overexpressing Mcl-1.
Mcl-1, an anti-apoptotic protein belonging to the Bcl-2 family of proteins, is upregulated in cancer cells and promotes tumor cell survival.

Physicochemical Properties

References

1. Cassier PA, et al. Br J Cancer. 2017 Oct 10;117(8):1089-1098.

URK-V595_COA

URK-V595_SDS

URK-V595_TDS

 

Note: All products of Ureiko are only used for scientific research or drug certificate declaration, and we do not provide products and services for any personal use

Why choose us?

• Our company culture is built around integrity, transparency, and customer focus.
• We provide reliable products to our customers with modern production scale, professional product technology, advanced manufacturing technology and comprehensive cost advantage.
• We are committed to providing fast and reliable shipping to our customers worldwide.
• We are looking forwards the opportunity to serve you.
• Our team of experts has a deep understanding of the science behind our Apoptosis Library products.
• Our company provides integrated services such as complete independent design and independent manufacturing of MIK665 CAS No.: 1799631-75-6. We are positioned to professionally manufacture high-quality products and provide perfect and fast after-sales service. Professional design and development team, professional production and manufacturing personnel, and professional sales and service personnel serve various industries.
• Our commitment to quality and customer satisfaction is second to none in the industry.
• We follow the general requirements of supply-side structural reform and adhere to innovation-driven development.
• We pride ourselves on our flexibility and ability to tailor our products and services to meet specific customer needs.
• We also provide professional technical guidance and fast business processing problems, so as to eliminate all worries for customers and focus on our main business.

Hot Tags: mik665 cas no.: 1799631-75-6, China mik665 cas no.: 1799631-75-6, agonists for nuclear receptor activation, agonists for protein fragment function, epigenetic library for epigenetic signalling, epigenetic library for epigenetic regulation of cell apoptosis, agonists for drug metabolism, agonists for inflammation research